On 13 May 2024, Boehringer Ingelheim (BI) announced a partnership with Cigna subsidiary Quallent Pharmaceuticals, under which Quallent will distribute high and low-concentration forms of BI’s citrate-free adalimumab biosimilar in the USA under its private label. BI will continue to market its adalimumab products.
BI’s high concentration Cyltezo® was approved by the FDA in May 2024 and a low concentration formulation has been on the US-market since July 2023.
BI is the second Humira® biosimilar manufacturer to partner with Quallent, with Alvotech announcing last month its US partnership with Quallent to supply Alvotech’s high-concentration interchangeable adalimumab biosimilar.